PT916670E - Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f - Google Patents
Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1fInfo
- Publication number
- PT916670E PT916670E PT98309321T PT98309321T PT916670E PT 916670 E PT916670 E PT 916670E PT 98309321 T PT98309321 T PT 98309321T PT 98309321 T PT98309321 T PT 98309321T PT 916670 E PT916670 E PT 916670E
- Authority
- PT
- Portugal
- Prior art keywords
- pyridines
- pyrrole
- ht1f
- ht1f agonists
- agonists
- Prior art date
Links
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 title abstract 3
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Battery Electrode And Active Subsutance (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/970,637 US5905084A (en) | 1997-11-14 | 1997-11-14 | 5-HTIF -agonists effective in treating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT916670E true PT916670E (pt) | 2003-09-30 |
Family
ID=25517243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98309321T PT916670E (pt) | 1997-11-14 | 1998-11-13 | Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5905084A (pt) |
| EP (1) | EP0916670B1 (pt) |
| JP (1) | JP2001522887A (pt) |
| KR (1) | KR20010032085A (pt) |
| CN (1) | CN1284874A (pt) |
| AT (1) | ATE240326T1 (pt) |
| AU (1) | AU1407299A (pt) |
| BR (1) | BR9814188A (pt) |
| CA (1) | CA2310248A1 (pt) |
| DE (1) | DE69814563T2 (pt) |
| DK (1) | DK0916670T3 (pt) |
| EA (1) | EA200000522A1 (pt) |
| ES (1) | ES2198657T3 (pt) |
| HR (1) | HRP20000297A2 (pt) |
| HU (1) | HUP0004317A3 (pt) |
| ID (1) | ID25478A (pt) |
| IL (1) | IL135634A0 (pt) |
| NO (1) | NO20002408L (pt) |
| PL (1) | PL340459A1 (pt) |
| PT (1) | PT916670E (pt) |
| TR (1) | TR200001724T2 (pt) |
| WO (1) | WO1999025348A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382247C (en) * | 1999-08-12 | 2010-09-28 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
| AU1570701A (en) * | 1999-10-19 | 2001-04-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the 5-hydroxytryptamine (serotonin) receptor 1e gene |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| BRPI0409211A (pt) | 2003-04-18 | 2006-03-28 | Lilly Co Eli | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| WO2005061439A1 (en) | 2003-12-17 | 2005-07-07 | Eli Lilly And Company | Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists |
| US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| MX2011010359A (es) | 2009-04-02 | 2012-02-23 | Colucid Pharmaceuticals Inc | Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida. |
| US8697876B2 (en) | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| TWI829107B (zh) | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007926A1 (en) * | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| CN1184425A (zh) * | 1995-03-20 | 1998-06-10 | 伊莱利利公司 | 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂 |
| JPH11513666A (ja) * | 1995-10-10 | 1999-11-24 | イーライ・リリー・アンド・カンパニー | Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤 |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
-
1997
- 1997-11-14 US US08/970,637 patent/US5905084A/en not_active Expired - Fee Related
-
1998
- 1998-11-13 PT PT98309321T patent/PT916670E/pt unknown
- 1998-11-13 ES ES98309321T patent/ES2198657T3/es not_active Expired - Lifetime
- 1998-11-13 EP EP98309321A patent/EP0916670B1/en not_active Expired - Lifetime
- 1998-11-13 EA EA200000522A patent/EA200000522A1/ru unknown
- 1998-11-13 CA CA002310248A patent/CA2310248A1/en not_active Abandoned
- 1998-11-13 HU HU0004317A patent/HUP0004317A3/hu unknown
- 1998-11-13 JP JP2000520781A patent/JP2001522887A/ja not_active Withdrawn
- 1998-11-13 KR KR1020007005209A patent/KR20010032085A/ko not_active Withdrawn
- 1998-11-13 AU AU14072/99A patent/AU1407299A/en not_active Abandoned
- 1998-11-13 DK DK98309321T patent/DK0916670T3/da active
- 1998-11-13 TR TR2000/01724T patent/TR200001724T2/xx unknown
- 1998-11-13 DE DE69814563T patent/DE69814563T2/de not_active Expired - Fee Related
- 1998-11-13 IL IL13563498A patent/IL135634A0/xx unknown
- 1998-11-13 WO PCT/US1998/024256 patent/WO1999025348A1/en not_active Ceased
- 1998-11-13 PL PL98340459A patent/PL340459A1/xx unknown
- 1998-11-13 HR HR20000297A patent/HRP20000297A2/hr not_active Application Discontinuation
- 1998-11-13 ID IDW20000837A patent/ID25478A/id unknown
- 1998-11-13 BR BR9814188-0A patent/BR9814188A/pt not_active Application Discontinuation
- 1998-11-13 CN CN98812914A patent/CN1284874A/zh active Pending
- 1998-11-13 AT AT98309321T patent/ATE240326T1/de not_active IP Right Cessation
-
2000
- 2000-05-09 NO NO20002408A patent/NO20002408L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69814563T2 (de) | 2004-04-08 |
| AU1407299A (en) | 1999-06-07 |
| WO1999025348A1 (en) | 1999-05-27 |
| KR20010032085A (ko) | 2001-04-16 |
| BR9814188A (pt) | 2000-10-03 |
| ATE240326T1 (de) | 2003-05-15 |
| HRP20000297A2 (en) | 2000-12-31 |
| CA2310248A1 (en) | 1999-05-27 |
| PL340459A1 (en) | 2001-02-12 |
| EP0916670B1 (en) | 2003-05-14 |
| EA200000522A1 (ru) | 2000-10-30 |
| HUP0004317A3 (en) | 2002-03-28 |
| DE69814563D1 (de) | 2003-06-18 |
| ID25478A (id) | 2000-10-05 |
| CN1284874A (zh) | 2001-02-21 |
| JP2001522887A (ja) | 2001-11-20 |
| NO20002408D0 (no) | 2000-05-09 |
| TR200001724T2 (tr) | 2000-11-21 |
| HUP0004317A2 (hu) | 2001-10-28 |
| IL135634A0 (en) | 2001-05-20 |
| ES2198657T3 (es) | 2004-02-01 |
| EP0916670A3 (en) | 2001-05-23 |
| DK0916670T3 (da) | 2003-09-15 |
| NO20002408L (no) | 2000-07-12 |
| US5905084A (en) | 1999-05-18 |
| EP0916670A2 (en) | 1999-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69725825D1 (de) | 5-HT1F-Agonisten | |
| NO944643D0 (no) | Protein-kinase-C-hemmere | |
| ATE168992T1 (de) | 7-substituierte-9-substituierte glycylamido-6- demethyl-6-deoxytetracycline | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| BR9916798A (pt) | 4-arilamino, 4-arilóxi e 4-ariltio diarilaminas e seus derivados como inibidores seletivos de mek | |
| ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
| NO20040845L (no) | Substituerte indeno[1,2-c]isokinolinderivater og deres anvendelse | |
| FI920023A0 (fi) | Heteroarylpiperazinfoereningar som antipsykotiska aemnen. | |
| PT882726E (pt) | Carbazol-carboxamidas como agonistas 5-ht1f | |
| TR200101978T2 (tr) | 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri. | |
| PT916670E (pt) | Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f | |
| SE9802937D0 (sv) | Novel compounds | |
| SE0003476D0 (sv) | Compounds | |
| DK1104419T3 (da) | N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse | |
| AR021502A1 (es) | Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso | |
| ES2086395T3 (es) | Fosfolipidos para el tratamiento de esclerosis multiple. |